Results 131 to 140 of about 296,448 (281)

Potential of Ginkgo biloba Extract to Intervene in Chronic Inflammation‐Related Diseases

Phytotherapy Research, EarlyView.
Chronic inflammation is a pathological mechanism underpinning many diseases. Ginkgo biloba extract (GBE) is well known for its anti‐inflammatory property. GBE and its active constituents have been shown to attenuate pro‐inflammatory cytokine production, suppress nuclear factor kappa B activation, restore redox homeostasis, and modulate disease‐relevant
Yipeng Lin, Inho Cho, Xue Zhu, Ke Wang, Ling Zhu, Wenchang Wong, Michael Murray, Fanfan Zhou   +7 more
wiley   +1 more source

Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options

Psoriasis: Targets and Therapy, 2013
Muhammad Haroon,1 Oliver FitzGerald,1 Robert Winchester2 1Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland; 2Division of Rheumatology, Columbia University College of Physicians and Surgeons, New York, NY, USA Abstract ...
Haroon M, FitzGerald O, Winchester R
doaj  

Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. [PDF]

Clin Rheumatol, 2023
Weinstein CLJ, Meehan AG, Lin J, Briscoe SD, Govoni M.   +4 more
europepmc   +1 more source

Local effects of adipose tissue in psoriasis and psoriatic arthritis

, 2017
Ilja L Kruglikov,1 Uwe Wollina2 1Scientific Department, Wellcomet GmbH, Karlsruhe, 2Department of Dermatology and Allergology, Hospital Dresden-Friedrichstadt Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany Abstract ...
Wollina U, Kruglikov IL
core  

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. [PDF]

RMD Open, 2023
Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E.   +13 more
europepmc   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada, Yoshiko Maeda, Miyuki Hasegawa, Motonobu Sakaguchi, Takamasa Hashimoto, Teruko Narusawa, Nobuyoshi Takabayashi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda   +9 more
wiley   +1 more source

CLINICAL ASSESSMENT IN PSORIATIC ARTHRITIS

, 2011
Due to the heterogenous clinical picture, with a possible combination in any individual patient of axial disease, peripheral arthritis, enthesitis and dactylitis, psoriatic arthritis (PsA) is difficult to assess.
C. Salvarani, N. Pipitone, M.G. Catanoso
core   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

Connecting the use of innovative treatments and glucocorticoids with the multidisciplinary evaluation through rule-based natural-language processing: a real-world study on patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. [PDF]

Front Med (Lausanne), 2023
Motta F, Morandini P, Maffia F, Vecellio M, Tonutti A, De Santis M, Costanzo A, Puggioni F, Savevski V, Selmi C.   +9 more
europepmc   +1 more source

Safety of Venom Immunotherapy in Pregnancy: A Multicentre Study

Allergy, EarlyView.
Venom immunotherapy (VIT) during pregnancy, when maintenance dose is well tolerated, can be continued. No increased risk of adverse effects to VIT or safety concerns for the pregnancy or the newborns were observed. No decreased efficacy of VIT, in case of re‐stings, was reported.
Matteo Martini, Giovanna Sfriso, Valerio Pravettoni, Marina Mauro, Donatella Preziosi, Francesca Vettorato, Giuseppe Lucchini, Mauro Pagani, Iuliana Badiu, Maria Pia Dolcher, Francesco Gaeta, Pietro Galati, Elisa Meucci, Elide Pastorello, Vincenzo Patella, Stefano Pucci, Chiara Roncallo, Eleonora Savi, Livio Simioni, Maria Beatrice Bilò, Patrizia Bonadonna   +20 more
wiley   +1 more source